



**Mailing Address:**  
ADAP Advocacy  
PO Box 846  
Nags Head, NC 27959

**Office Address:**  
1630 Connecticut Ave, NW  
Suite 500  
Washington, DC 20009

**CEO:**  
Brandon M. Macsata  
Washington, D.C.

**Board of Directors:**

**Co-Chair**  
Jen Laws  
Slidell, LA

**Co-Chair**  
Guy Anthony  
Brooklyn, NY

**Secretary**  
Lisa Johnson-Lett  
Birmingham, AL

**Treasurer**  
Wanda Brendle-Moss, R.N.  
Winston-Salem, NC

Erin Darling, Esq.  
Washington, DC

Robert "Bobby" Dorsey, Esq.  
La Plata, MD

Lyne Fortin, B.Pharm, MBA  
Montreal, Canada

Hilary M. Hansen  
Washington, DC

Maria Mejia  
Tamarac, FL

Theresa Nowlin  
Dorchester, MA

Shabbir Imber Safdar  
San Francisco, CA

Jennifer Vaughan  
Watsonville, CA

Marcus A. Wilson  
Orlando, FL

**Directors Emeritus:**  
Michelle Anderson  
William Arnold – *in memoriam*  
John D. Kemp, Esq.  
Gary Rose – *in memoriam*  
Joyce Turner Keller  
Rani Whitfield, M.D.

## **ADAP Advocacy Applauds Introduction of the 340B ACCESS Act**

### ***Urges Congress to enact long-overdue reforms to the 340B Drug Pricing Program***

For Immediate Release:  
October 9, 2025

Media Contact:  
[info@adapadvocacy.org](mailto:info@adapadvocacy.org)

WASHINGTON, D.C. – ADAP Advocacy applauded the introduction of the “[340B Affording Care for Communities and Ensuring a Strong Safety-net](#)” (ACCESS) Act, or H.R. 5256, introduced in the House of Representatives in September 2025.

Brandon M. Macsata, CEO of ADAP Advocacy, stated, “**The 340B Drug Pricing Program is a vital source of funding for programs that serve poor and rural patients, but too many hospital systems and other large covered entities have been playing fast and loose with a statute that, for far too long, has lacked the necessary transparency and enforcement mechanisms to ensure that those funds are reinvested into care for the patients it was created to serve. The 340B ACCESS Act represents a real course correctional first step toward achieving those goals.**”

Congress established the 340B Drug Pricing Program to enable nonprofit healthcare providers to optimize their use of limited resources, ensuring access to medications for uninsured patients with acute and chronic health conditions and disorders. The 340B ACCESS Act would amend Section 340B(b) of the Public Health Service Act (42 U.S.C. 256b(b)) by:

- Codifying the definition of “Patient” to define which patients are eligible, for how long, and under which circumstances;
- Establishing eligibility requirements for hospitals, with specific requirements varying by hospital type, to ensure that the program serves actual safety net hospitals;
- Establishing statutory standards for child site eligibility and requiring covered entities to demonstrate to HHS that each child site satisfies those new standards prior to participating in the 340B Program;
- Introducing restrictions on Pharmacy Benefit Managers (PBMs), contract pharmacies, and third-party administrators to guard against for-profit, 340B supply chain middlemen from making excessive profits off the program; and,
- Codifying reporting and transparency requirements for 340B covered entities.

To learn more about ADAP Advocacy, the 340B Program, or the 340B ACCESS Act, please email [info@adapadvocacy.org](mailto:info@adapadvocacy.org).

####

**About ADAP Advocacy:** ADAP Advocacy's mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.